Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) EPS (diluted)
Charles River Laboratories International, Inc.'s EPS (diluted) for fiscal 2025 was −$2.91, compared with $0.20 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.85. Over the past ten years it has ranged from −$2.91 (fiscal 2025) to $9.48 (fiscal 2022) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 45th of 52 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.91 | — |
| FY2024 | $0.20 | (97.83%) |
| FY2023 | $9.22 | (2.74%) |
| FY2022 | $9.48 | 24.74% |
| FY2021 | $7.60 | 5.56% |
| FY2020 | $7.20 | 42.01% |
| FY2019 | $5.07 | 9.74% |
| FY2018 | $4.62 | 81.89% |
| FY2017 | $2.54 | (21.36%) |
| FY2016 | $3.23 | 3.19% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.03 | — |
| Mar 2026 | −$0.30 | — |
| Dec 2025 | −$5.62 | — |
| Sep 2025 | $1.10 | 3.77% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MEDP Medpace Holdings, Inc. compare | $17.06 |
| LH Labcorp Holdings Inc. compare | $12.09 |
| DGX Quest Diagnostics Incorporated compare | $9.42 |
| RVTY Revvity Inc. compare | $2.10 |
| QGEN QIAGEN N.V. compare | $1.95 |
| ICLR ICON PLC compare | $0.66 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| GH Guardant Health, Inc. compare | −$3.49 |
| CRL Charles River Laboratories International, Inc. | −$4.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement